NCT05637580 is a clinical trial of Timing of drug administration in Non Small Cell Lung Cancer, sponsored by Guangdong Provincial People's Hospital.

Who is sponsoring NCT05637580?

NCT05637580 is sponsored by Guangdong Provincial People's Hospital.

What drugs are being tested in NCT05637580?

Interventions in NCT05637580: Timing of drug administration.

What condition does NCT05637580 study?

NCT05637580 studies Non Small Cell Lung Cancer, Immunotherapy, Chemotherapy, Tumour, Residual.

Is NCT05637580 still recruiting?

NCT05637580 is currently completed. Last updated 5 December 2022.

Last reviewed 2022-12-05 · How we verify

NCT05637580

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC

Completed Last updated 5 December 2022

What this trial tests

trial testing Timing of drug administration in Non Small Cell Lung Cancer in 110 participants. Completed in 1 July 2022.

Timeline

20 May 2019

Primary endpoint
1 July 2022

1 July 2022

Quick facts

Lead sponsor	Guangdong Provincial People's Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	110
Start date	20 May 2019
Primary completion	1 July 2022
Estimated completion	1 July 2022
Sites	1 location across China

Drugs / interventions tested

Timing of drug administration — full drug profile →

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Immunotherapy — all drugs for Immunotherapy →
Chemotherapy — all drugs for Chemotherapy →
Tumour, Residual — all drugs for Tumour, Residual →

Sponsor

Guangdong Provincial People's Hospital

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer or Immunotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date. Patients with initially unresectable NSCLC underwent immunochemotherapy and response to treatment was assessed after every two treatment cycles. Clinicopathologic features of patients including epidemiological data, clinical manifestations, operation strategies, pathological findings, and prognostic information were recorded and evaluated.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Integration of circadian rhythms and immunotherapy for enhanced precision in brain cancer treatment.
Quist M, van Os M, van Laake LW, Bovenschen N, et al · · 2024 · cited 11× · PMID 39413708 · DOI 10.1016/j.ebiom.2024.105395
Circadian clocks and adaptive immune function: from mechanisms to therapeutic applications.
Szredzka A, Chwastowicz A, Pergoł J, Matryba P. · · 2025 · PMID 41415271 · DOI 10.3389/fimmu.2025.1697854

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Guangdong Provincial People's Hospital trials

Trials by the same sponsor.

NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05637580 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
Last refreshed: 5 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05637580.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing